Avon, Connecticut Dec 20, 2025 (Issuewire.com) - MedResults Network (MRN), one of the nation’s largest group purchasing organizations for aesthetic and surgical practices, has named Resiliélle® Age Zero™ Exosomes as its exclusive exosome partner following a multi-year nationwide search.
After visiting eight laboratories and evaluating data, leadership, and manufacturing processes, MRN President and CEO Jeff Routledge confirmed Resiliélle’s Age Zero™ platform as the most advanced and scientifically validated exosome solution for medical aesthetics.
“In a marketplace filled with questionable claims, one company stood above the rest,” said Routledge. “Resiliélle Age Zero™ Exosomes are fully characterized, verified through independent testing at a Harvard Medical School Core Laboratory, and represent the true medical-grade standard in regenerative aesthetics.”
Raising the Standard for Exosome Science
Independent testing has shown that most exosome products on the market contain few or no intact exosomes. In contrast, through independent laboratory testing, Resiliélle® Age Zero™ Exosomes have demonstrated structurally intact bilipid membranes with verified internal cargo, confirmed through Transmission Electron Microscopy (TEM), Immunogold staining, NanoSight NS300 analysis, CD marker profiling, and proteomic characterization. Each batch is third-party tested in CLIA-certified U.S. laboratories to ensure quality, consistency, and verified bioactivity.
“Together with Resiliélle, we’ll bring real science and education to our members,” added Routledge. “Our goal is to educate providers on the importance of verified exosomes and how they can safely enhance aesthetic outcomes.”
Industry-Leading Partnership
This partnership makes Resiliélle Age Zero™ Exosomes available to more than 4,000 MRN member practices nationwide.
“We’re honored to partner with MedResults Network,” said Michael C. Crowley, JD, Chairman of Resiliélle. “Together, we’ll expand access to verified, bioactive exosomes and help aesthetic providers deliver safer, more effective regenerative treatments.”
Resiliélle®, co-led by Michael Crowley and his daughter Erin Crowley, M.Eng., together with their team of scientists and engineers, combines over a century of stem cell and exosome research with patent-pending manufacturing technologies to produce the world’s most fully characterized exosome platform, which is supported by a commercial team with decades of experience in the aesthetic industry.
For more information, visit medresultsnetwork.com/introducing-resilielle-age-zero-exosomes.
About MedResults Network
Founded in 2008, MedResults Network is a leading Group Purchasing Organization (GPO) serving more than 4,000 aesthetic practices and med spas nationwide. MRN connects members to vetted vendors and exclusive partnerships that drive compliance, safety, and savings. Learn more at medresultsnetwork.com.
About Resiliélle®
RESILIÉLLE COSMETICS LLC located in Rochester, NY is redefining regenerative aesthetics with its Age Zero™ Exosomes. Backed by 20+ years of stem cell and hematology research, Resilielle has pioneered the world’s most fully characterized, medically validated exosome platform. Led by Michael C. Crowley, JD (Chairman) and Erin Crowley, MEng (CEO), Resilielle combines regulatory integrity, clinical science, and patent-pending manufacturing to set the global benchmark for exosome-based aesthetics and is supported by a clinical and commercial team with decades of experience in the aesthetics industry.
Media Contact
Caralina Wigfield *****@medresultsnetwork.com 20 Tower Lane, Ste. 500 https://medresultsnetwork.com/
